# SAM #12481254

DHA sole-source award for Novartis LUTATHERA and PLUVICTO radioligand therapies

**Buyer:** Defense Health Agency
**Posted:** October 08, 2026
**Identifier:** 12481254
**NAICS:** 325412

The Defense Health Agency awarded Novartis Pharmaceuticals Corporation a sole-source purchase of radioligand therapies for Walter Reed National Military Medical Center.
- **Government buyer:** Defense Health Agency, for the Nuclear Medicine Division, Department of Radiology, at Walter Reed National Military Medical Center.
- **OEM and vendor:** **Novartis Pharmaceuticals Corporation** is the named manufacturer and awardee.
- **Products requested:**
  - **LUTATHERA** (lutetium Lu 177 dotatate), a radioligand therapy product; quantity and part number not specified.
  - **PLUVICTO** (lutetium Lu 177 vipivotide tetraxetan), a targeted radioligand therapy for certain types of prostate cancer; quantity and part number not specified.
- **Notable requirement:** The award is sole-source to Novartis. The notice cites continued product delivery and continuity of patient care as reasons for the direct award.
- **Period and value:** The notice does not specify a period of performance or contract value.

### Description

<p>Clinical Utility: It is used for targeted radioligand therapy for specific types of prostate cancer within the Nuclear Medicine Division of the Department of Radiology at WRNMMC. Novartis Pharmaceuticals Corporation is the sole source for Pluvicto. Therefore, the recommended course of action is to award a contract directly to Novartis. This approach is deemed to be in the government&#39;s best interest to ensure the seamless delivery of these critical supplies and maintain continuity of patient care at WRNMMC. The acquisition will be treated as a sole-source procurement.</p>

[View original listing](https://sam.gov/opp/b282dc9e8acc4a928ab3a5823a5dd0f3/view)